机构:[1]State Key Laboratory of Quality Research in Chinese Medicine The Institute for Translational Medicine Macau University of Science and Technology Avenida Wai Long, Taipa, Macau, P.R. China[2]Institute of Consun Co. for Chinese Medicine in Kidney Diseases Guangdong Consun Pharmaceutical Group Guangzhou, P.R. China[3]University Hospital, Macau University of Science and Technology Foundation Macau, P.R. China
Diabetes mellitus (DM) often accompanies liver dysfunction. Astragali Radix is a traditional Chinese herbal medicine that is widely administrated to ameliorate the symptoms of diabetes as well as liver dysfunction, but its acting mechanism is still not yet fully recognized. Advanced glycation end products (AGEs) play a key role in promoting diabetic organ dysfunction. Both hyperglycemia and AGEs can induce insulin resistance, hepatocyte damage and liver dysfunction. We designed this study to explore the effects of the phytoestrogen Calycosin, a major active component of Astragali Radix, on AGEs-induced glucose uptake dysfunction in the hepatocyte cell line and relevant mechanisms. MTT and BrdU methods were applied to evaluate cell viability. 2-NBDG was used to observe glucose uptake by a live cell imaging system. Immunofluorescence method was carried out to investigate GLUT1, GLUT4, and RAGE protein expressions on cell membrane. cAMP content was determined by an EIA method. We found Calycosin concentration-dependently ameliorated AGEs-induced hepatocyte viability damage. AGEs dramatically reduced basal glucose uptake in hepatocytes, and this reduction could be reversed by Calycosin administration. By immunofluorescence detection, we observed that Calycosin could inhibit AGEs-induced GLUT1 expression down-regulation via estrogen receptor (ER). Furthermore, Calycosin decreased AGEs-promoted RAGE and cAMP elevation in hepatocytes. These findings strongly suggest that Calycosin can ameliorate AGEs-promoted glucose uptake dysfunction in hepatocytes; the protection of cell viability and ER-RAGE and GLUT1 pathways play a significant role in this modulation.
基金:
Science and Technology Development Fund of Macau
(FDCT: 049/2012/A2; FDCT: 071/2014/A).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2014]版:
大类|3 区医学
小类|2 区全科医学与补充医学3 区医学:内科
最新[2025]版:
大类|2 区医学
小类|2 区全科医学与补充医学2 区医学:内科
第一作者:
第一作者机构:[1]State Key Laboratory of Quality Research in Chinese Medicine The Institute for Translational Medicine Macau University of Science and Technology Avenida Wai Long, Taipa, Macau, P.R. China[*1]State Key Laboratory of Quality Research in Chinese Medicine, The Institute for Translational Medicine, Faculty of Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau 999078, P.R. China.
共同第一作者:
通讯作者:
通讯机构:[1]State Key Laboratory of Quality Research in Chinese Medicine The Institute for Translational Medicine Macau University of Science and Technology Avenida Wai Long, Taipa, Macau, P.R. China[2]Institute of Consun Co. for Chinese Medicine in Kidney Diseases Guangdong Consun Pharmaceutical Group Guangzhou, P.R. China[*1]State Key Laboratory of Quality Research in Chinese Medicine, The Institute for Translational Medicine, Faculty of Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau 999078, P.R. China.
推荐引用方式(GB/T 7714):
Xu Youhua,Xiong Jianfeng,Zhao Yonghua,et al.Calycosin Rebalances Advanced Glycation End Products-Induced Glucose Uptake Dysfunction of Hepatocyte In Vitro.[J].The American journal of Chinese medicine.2015,43(6):1191-210.doi:10.1142/S0192415X15500688.
APA:
Xu Youhua,Xiong Jianfeng,Zhao Yonghua,He Bao,Zheng Zhaoguang...&Zhu Quan.(2015).Calycosin Rebalances Advanced Glycation End Products-Induced Glucose Uptake Dysfunction of Hepatocyte In Vitro..The American journal of Chinese medicine,43,(6)
MLA:
Xu Youhua,et al."Calycosin Rebalances Advanced Glycation End Products-Induced Glucose Uptake Dysfunction of Hepatocyte In Vitro.".The American journal of Chinese medicine 43..6(2015):1191-210